Examining Disparities in the Management of NSCLC
2023 NACLC Opening Keynote Speaker Marjory Charlot, MD, MPH, MSc, presented “Equities and Disparities,” focusing on disparities in the management of NSCLC....
2023 NACLC Opening Keynote Speaker Marjory Charlot, MD, MPH, MSc, presented “Equities and Disparities,” focusing on disparities in the management of NSCLC....
Spread through air space (STAS) is a novel invasive pattern of lung adenocarcinoma (LUAD), and preoperative knowledge of STAS status is helpful in choosing an appropriate surgical approach.T...
Lung cancer with the highest incidence and mortality in the world. Immune checkpoint inhibitors (ICIs), can bring long-term survival benefits to patients, but also can bring immune-related a...
The rate of new lung cancer cases has decreased, and survival has improved over the past 5 years, according to the State of Lung Cancer 2023 report published by the American Lung Association...
Researchers described a new familial lung cancer caused by an inherited mutation in EGFR in a study published in the Journal of Clinical Oncology. Geoffrey R. Oxnard, MD, and colleagues enro...
Given its potential to impact health, physicians should not hesitate to refer families with a strong history of cancer for genetic counseling and testing....
Some species have been shown to have pharmacological properties such as activity against cancer, and it is also used as a traditional herbal medicine in many rural parts of the world. The (...
The treatment resistance is a problem for lung cancer. In this study, we used a vitro tissue culturing system to select a new therapy strategy for a patient with tyrosine kinase inhibitors (...
Alectinib, a second-generation anaplastic lymphoma kinase (ALK) inhibitor, has been shown to be effective for patients with ALK-positive non-small cell lung cancer (NSCLC). However, alectini...
This study aimed to investigate the effect of Jiedu Fuzheng decoction (JFD) in non-small cell lung cancer (NSCLC) and its potential therapeutic mechanism.We prepared JFD-medicated serum from...
An increasing number of small nucleolar RNA host genes (SNHGs) have been revealed to be dysregulated in lung cancer tissues, and abnormal expression of SNHGs is significantly correlated with...
1. Median PFS and OS between the tiragolumab and control arms were similar 2. Treatment-related AEs that were grade 3/4 occurred in 52.7% in the tiragolumab arm and 55.7% in the control a...
Click here to read this study in NEJM. ©2023 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. In...
Click here to read this study in NEJM. ©2023 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire...
The initiation biomarker-driven trials have revolutionized oncology drug development by challenging the traditional phased approach and introducing basket studies. Notable successes in non-s...
1. The progression-free survival in berzosertib with topotecan vs topotecan alone was not statistically significant, but the overall survival was significant. 2. Grade ≥3 treatment-relat...
Although adjuvant systemic therapy (AT) has demonstrated improved survival in patients with resected non-small cell lung cancer, it remains underutilized. Recent trials demonstrating improve...
Bookmark Click here to read this study in NEJM. VA design by Bryan Sun. ©2023 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from...
Mutation in KRAS protooncogene represents one of the most common genetic alterations in NSCLC and has posed a great therapeutic challenge over the past ~ 40 years since its discovery. How...
Soluble LAG-3 protein eftilagimod alpha combined with pembrolizumab shows promising clinical efficacy as first-line treatment for advanced or metastatic NSCLC....
The latest articles and insights from your colleagues in your specialty(ies) of choice.
Insights from the leaders in medical research, trending topics in clinical medicine, and perspectives from your colleagues.
Subscribe to our free Newsletters to receive weekly emails, and even get a laugh or two from our medical cartoons.